Crinetics Pharmaceuticals Inc CRNX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/21/24 EDT
49.50quote price arrow down-1.12 (-2.21%)
Volume
1,050,199
52 week range
15.76 - 52.03
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close49.50
  • 52 Week High52.03
  • 52 Week High Date05/17/24
  • 52 Week Low15.76
  • 52 Week Low Date09/08/23

Key Stats

  • Market Cap3.904B
  • Shares Out78.86M
  • 10 Day Average Volume0.96M
  • Dividend-
  • Dividend Yield-
  • Beta0.68
  • YTD % Change39.12

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close49.50
  • 52 Week High52.03
  • 52 Week High Date05/17/24
  • 52 Week Low15.76
  • 52 Week Low Date09/08/23
  • Market Cap3.904B
  • Shares Out78.86M
  • 10 Day Average Volume0.96M
  • Dividend-
  • Dividend Yield-
  • Beta0.68
  • YTD % Change39.12

RATIOS/PROFITABILITY

  • EPS (TTM)-3.77
  • P/E (TTM)-13.13
  • Fwd P/E (NTM)-14.49
  • EBITDA (TTM)-246.87M
  • ROE (TTM)-40.76%
  • Revenue (TTM)1.974M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-11,641.13%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Crinetics Pharmaceuticals Inc

 

Profile

MORE
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic...
Wendell Wierenga Ph.D.
Independent Chairman of the Board
R. Scott Struthers Ph.D.
President, Chief Executive Officer, Co-Founder, Director
Jeff Knight
Chief Operating Officer
Marc Wilson CPA
Chief Financial Officer
Address
10222 Barnes Canyon Rd Bldg 2
San Diego, CA
92121-2711
United States

Top Peers

SYMBOLLASTCHG%CHG
ALPN
NUVL
Nuvalent Inc
69.73-1.20-1.69%
MDGL
Madrigal Pharmaceuticals Inc
242.49+10.39+4.48%
SWTX
SpringWorks Therapeutics Inc
42.98+0.52+1.22%
BHVN
Biohaven Ltd
38.72-0.60-1.53%